Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Scope of the Report:
mRNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of mRNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
Since the product still in development stage, so companies rely mainly on investment or cooperation to obtain funding to continue research and development.
The research of mRNA Vaccines & Therapeutics to treat infectious disease, cancer and others. The expenses on infectious disease is the most, with the market share of 46% in 2017.
The worldwide market for mRNA Vaccines & Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new WMR study.
This report focuses on the mRNA Vaccines & Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Standardization Of Cancer Treatment MRNA Vaccine
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe mRNA Vaccines & Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of mRNA Vaccines & Therapeutics, with price, sales, revenue and global market share of mRNA Vaccines & Therapeutics in 2017 and 2018.
Chapter 3, the mRNA Vaccines & Therapeutics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the mRNA Vaccines & Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, mRNA Vaccines & Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe mRNA Vaccines & Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.